Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The experiment is divided into two parts: Part 1 and Part 2.Part 1 was the initial treatment patient and Part 2 was the treated patient.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunshine Lake Pharma Co., Ltd.
• Treatments: Antiviral Agents; Entecavir; Ritonavir

Criteria

Inclusion Criteria:

• Chronic HBV infection population

• HBeAg positive

• HBsAg≥250 IU/mL

• No cirrhosis

Exclusion Criteria:

• AST>5×ULN

• Platelet count less than 90E+09/L

• TBil>1.5×ULN

• albumin<35 g/L

• INR>1.5

• AFP>50 ng/mL